Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · IEX Real-Time Price · USD
0.303
+0.004 (1.27%)
Jul 22, 2024, 11:19 AM EDT - Market open
Galmed Pharmaceuticals Employees
As of December 31, 2023, Galmed Pharmaceuticals had 8 total employees, including 3 full-time and 5 part-time employees. The number of employees decreased by 2 or -20.00% compared to the previous year.
Employees
8
Change (1Y)
-2
Growth (1Y)
-20.00%
Revenue / Employee
n/a
Profits / Employee
-$794,625
Market Cap
1.80M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Nuwellis | 59 |
| NovaBay Pharmaceuticals | 26 |
| Windtree Therapeutics | 20 |
| Seelos Therapeutics | 16 |
| Azitra | 10 |
| PainReform | 7 |
| 180 Life Sciences | 4 |
| IMAC Holdings | 4 |
GLMD News
- 3 months ago - Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PRNewsWire
- 4 months ago - Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - PRNewsWire
- 8 months ago - Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PRNewsWire
- 10 months ago - Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis - PRNewsWire
- 10 months ago - Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PRNewsWire
- 1 year ago - Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC - PRNewsWire
- 1 year ago - Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments - PRNewsWire